Therapeutic AIDS vaccines, Raising hopes and many questions, Ethics, antiretrovirals and prevention trials, To our readers: A farewell, Treatment in vaccine trials and AIDS in Brazil, Weighing the burden of disease, Vaccine Briefs
By Emily Bass*
The recent decisions by several AIDS vaccine trial sponsors to ensure access to antiretrovirals (ARVs) for trial participants who become infected with HIV come after years of debate and discussion about the ethical implications of providing—or not providing—these powerful medications to trial volunteers.
Vaccine trial sponsors’ new approaches to providing antiretrovirals for trial volunteers
Are they feasible and is their development a separate endeavor from preventive vaccines?
By Patricia Kahn, Ph.D.*
I’m writing to say adieu from my perch at the IAVI Report. In August 2003, after three years as editor of the newsletter, I left IAVI to resume freelance writing, editing and teaching.
Mauro Schechter MD, Ph.D is one of the leading figures in the field of AIDS in Brazil, and his renown now spreads beyond his home country to the international sphere.
By Roberto Fernandez-Larsson, Ph.D.*
IAVI and industry/academic partners begin two phase I HIV vaccine trials in December
How will diseases other than HIV affect AIDS vaccine trial design?